The histological characteristics of alcoholic liver disease (ALD) and non-alcoholic steatohepatitis (NASH) related to overweight and obesity suggest the presence of partly common physiopathological mechanisms. We reported that the ponderal overload was an independent risk factor of alcoholic cirrhosis. The adipose tissue was considered for a long time as a simple place of storage of fat. However, it is now recognized that the adipose tissue can secrete cytokines called adipokines.

The adipose tissue can secrete others cytokines such as TNF α, lL6, IL10 and IL1-Ra. Increase in the production of the leptin and TNFα by the adipose tissue after alcohol administration in the rat, as well as the role of leptin in inflammation and liver fibrogenesis in the murine model of chemical hepatotoxicity strongly suggest that activation of adipocytes by alcohol can explain the strong correlation observed between the body mass index (BMI) and the severity of ethanol-induced liver injury. Conversely, it was suggested in a murine model that the reduction in adiponectin production would sensitize the liver with the toxicity of alcohol. The PPAR α and γ are the receptors which play a role both in inflammation and glucid and lipid metabolism. Taking into account the inhibiting role of PPAR α on the proliferation of the hepatic stellate cells, responsible for the fibrosis, the PPARs could also be implied in the relation between the overweight and the hepatic fibrosis in the alcoholic.

The aim of this project is to demonstrate that adipokines, as well as the PPAR α et γ are implied in the intensity of the steatosis and in the regulation of the inflammatory process and the hepatic fibrogenesis in alcoholic liver disease. In order to prove this hypothesis, we will study among patients having a ALD at various stages of histological severity: 1) the hepatic and subcutaneous abdominal adipose tissue expression of the PPAR α and PPAR γ 2)the hepatic and subcutaneous abdominal adipose tissue expression of the TNF α, the IL1Ra, the IL6 and the IL10; 3)the hepatic and subcutaneous abdominal adipose tissue expression of the adipokines (leptin, adiponectin, resistin); 4) the serum adipokine values, the cynetic of the mRNA expression and of the serum adipokine values after 7 days of alcohol withdrawal 50 patients will be studied (25 having ALD without cirrhosis, with or without acute alcoholic hepatitis (AAH) and 25 having alcoholic cirrhosis with or without AAH). A part of liver biopsy will be frozen in a dry tube. The percutaneous adipose tissue will be obtained with a ponction on the abdominal level at the time of inclusion of the patients having AAH and, for the second time, after 7 days of alcohol withdrawal, than will be frozen. The TNF α, the IL1Ra, the IL6, the IL10, the leptin, the adiponectin and the resistin expression as well as the hepatic and adipose tissue PPAR α and γ will be evaluated by PCR in real time. The serum concentration of the adipokines (leptin, adiponectin, resistin) will be measured by ELISA or RIA.

If our hypothesis is true, severity of liver lesions (steatosis, AAH, fibrosis) could be positively correlated with the expression in the liver and the adipose tissue and/or the serum values of the anti-inflammatory cytokines and adipokines (TNF α, IL6, leptin, resistin) and negatively with the cytokines and adipokines which are potentially anti-inflammatory (IL1Ra, IL10, adiponectin). We also expect to find a negative correlation between the amount of hepatic and adipose tissue PPAR-α and PPAR-γ mRNA and the severity of the liver disease.

• Alcoholic Hepatitis
• Alcoholic Cirrhosis

Inclusion Criteria:

• Alcoholic patients of both sex aged from 18 to 75, hospitalized for alcoholic liver disease.
• HBs antigen negative, HIV negative, anti –VHC negative
• daily consumption exceeded 40-50 grams per day during the last year
• elevated AST level and liver biopsy during the hospitalisation Patients who signed the informed consent document
• patients affiliated to the national health insurance system (sécurité sociale)

Exclusion Criteria:

• patients having another cause than alcohol for liver injury - hepatocellular carcinoma or another developing cancer, severe associated pathology (cardiac disease, respiratory insufficency, severe psychiatric problems), pancreatitis, infection, diabetes or a dyslipidemia
• patients treated with fibrates or other hypolipidic drugs, oral antidiabetics
• or insulin
• patients having hemostasis which does not permit the transcostal liver biopsy, platelet level <60 giga/l, or Quick test < 50 %, or (TCA higher than 1,5 times the time of the witness)
• patients refuse an adipose tissue biopsy
• patients treated with long-duration dose of clopidogrel (Plavix®)
• patients who significantly diminished alcohol consumption in comparison with the average consumption during the year preceding the inclusion
• patients not-affiliated to the national health insurance system (sécurité sociale)